LOVELAND, Colo., July 28, 2015 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and other specialty veterinary products, announced today the availability of the new Element i® Immunodiagnostic Analyzer. Element i performs immediate in-clinic testing and screening for key health concerns, including thyroid disorders, Cushing's disease and Addison's Disease. Heska's Element i is a compact bench top analyzer that delivers rapid immunoassay testing, including Total T4, Cortisol and the very first in-clinic TSH test available to North American veterinary hospital clients. The Heska Element i and its host of testing supplies will soon be available for order through Heska Corporation and Henry Schein Animal Health.
More about the Element i from Heska
The Element i platform currently delivers results in under ten minutes, from three very important, individual, accurate, and quantitative immunodiagnostic assays. Heska's Element i leverages a host of advanced technologies and breakthroughs, including Fuji-Film's trusted SPF Fluorometery, the latest algorithms, software and connectivity, and ease and accuracy features such as auto-dilution.
Element i stands in a class of its own by meeting the important challenge of providing veterinarians with a point of care TSH test. Following identification of an abnormal Total T4 screen, TSH results greatly increase the specificity of testing for hypothyroidism in dogs. Now and for the first time ever, the Heska Element i eliminates worry, expense, and treatment challenges shouldered by those waiting for TSH results from an outside reference laboratory.
Steve Eyl, Executive Vice President of Commercial Operations for Heska, said, "The addition of Element i® compliments our leading chemistry, hematology, and blood gases suite. While others are launching only limited Total T4 tests on dated platforms, Heska again leapfrogs the competition with the first ever in-house immunoassay for TSH. Element i will save veterinarians and their clients from waiting, worry, doubt, and expense by instantly and precisely completing the picture only hinted at by an abnormal Total T4 result. Total T4 has long been used to screen for thyroid disorders. But Total T4 is only a partial and imprecise screen of a highly complex, yet common diagnosis that can and should be confirmed with a specific TSH result. TSH testing for specific thyroid function has never been available at the point of care, where veterinarians, patients, and their owners need it most. Prior to the release of the new Element i, the only option for obtaining precise TSH results following an abnormal Total T4 screen was to obtain and ship off samples to a remote reference laboratory. Today, with Heska's new Element i, details, answers and treatments are just minutes away. Pet care professionals can now have a new confidence and perspective on thyroid function by testing for both Total T4 and TSH in the exam room."
Heska Corporation (NASDAQ: HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include blood testing instruments and supplies, digital imaging products, software and services, and single use products and services such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to the expected technical performance of any product; uncertainties related to how veterinarians may utilize a particular product in practice; uncertainties related to the perception of Heska's current and future product, and the technical performance of such products, by Heska's customers; risks related to Heska's reliance on third-parties in product development; risk related to Heska's reliance on third-parties to manufacture products; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
SOURCE Heska Corporation